Market Place
Sourcing Support
Transcenta Shows Efficacy of Osemitamab in G/GEJ Cancer at ESMO 2024
18 Sep 2024 //
PR NEWSWIRE
Transcenta Holding Limited (Stock Code: 6628.HK) Announce 2024 Interim Results
29 Aug 2024 //
PR NEWSWIRE
Transcenta collaborates Agilent to develop Claudin18.2 to support Osemitamab
09 Apr 2024 //
PHARMABIZ
Transcenta Collab with Agilent to Develop a Claudin18.2 Companion Diagnostic
08 Apr 2024 //
PR NEWSWIRE
Transcenta Announces the Publication of Results of [177Lu]Lu-TST001 Radionuclide Antibody Conjugate
13 Dec 2023 //
PR NEWSWIRE
Transcenta Unveils Data from Osemitamab as First-Line Treatment for G/GEJ Cancer
23 Oct 2023 //
PR NEWSWIRE
FDA Grants Transcenta Clearance to Proceed with Phase III Trial of Osemitamab
03 Oct 2023 //
PR NEWSWIRE
Transcenta to Present Three Study Results at ESMO 2023
15 Aug 2023 //
PR NEWSWIRE
Transcenta Anti-sclerostin Monoclonal Antibody TST002 Received Approval
31 Jul 2023 //
PR NEWSWIRE
TST002 Received Approval from China CDE to Initiate Phase II Clinical Trial
30 Jul 2023 //
PR NEWSWIRE
Transcenta Presented PFS Data by CLDN18.2 Level from PhI/II Study of Osemitamab
30 Jun 2023 //
PR NEWSWIRE
Transcenta Presents Updated Data of Osemitamab in Combination with CAPOX
05 Jun 2023 //
PR NEWSWIRE
Transcenta Holding to Hold 2023 ASCO Business Update call Conference.
02 Jun 2023 //
PR NEWSWIRE
Transcenta Announces Encouraging Ph I Clinical Data of TST002
16 May 2023 //
PR NEWSWIRE
Transcenta to Present Two Clinical Trial Progress at ASCO 2023
08 May 2023 //
PR NEWSWIRE
Completion of Enrollment in Cohorts C and G of China PhII Study of Osemitamab
02 May 2023 //
PR NEWSWIRE
Transcenta`s Osemitamab Targeting Claudin18.2 Granted Orphan Drug Designation
29 Mar 2023 //
PR NEWSWIRE
Transcenta Announces First Patient Dosed in the U.S. Study of Antibody TST003
22 Mar 2023 //
PR NEWSWIRE
Transcenta to Present Two Preclinical Studies at AACR 2023
22 Mar 2023 //
PR NEWSWIRE
Transcenta Holding Limited to Hold 2022 Annual Results Release Conference
20 Mar 2023 //
PR NEWSWIRE
Results of CLDN18.2-targeting Immuno-PET Probe
03 Mar 2023 //
PR NEWSWIRE
US FDA clears Transcenta’s IND for Rett syndrome treatment
24 Jan 2023 //
PHARMACEUTICAL TECHNOLOGY
Transcenta to Present "Trial in Progress" at ASCO-GI for TST001 with Nivolumab
17 Jan 2023 //
PR NEWSWIRE
Transcenta Presented Two Scientific Posters at SITC 2022 Annual Meeting
10 Nov 2022 //
PRNEWSWIRE
Transcenta to Hold 3 Exchange Sessions on Post-SITC Business Update TST003 data
09 Nov 2022 //
PRNEWSWIRE
Transcenta to Participate in Four Upcoming Conferences
24 Oct 2022 //
PRNEWSWIRE
Transcenta to Present Two Scientific Posters at SITC 2022 Annual Meeting
13 Oct 2022 //
PRNEWSWIRE
Transcenta Received IND Clearance from FDA for TST004
04 Oct 2022 //
PRNEWSWIRE
Transcenta Received IND Clearance from FDA for TST003
14 Sep 2022 //
PRNEWSWIRE
Transcenta Releases Interim Safety Data of the TST001
12 Sep 2022 //
PRNEWSWIRE
Transcenta Appoints Dr. Caroline Germa as Executive VP, GMD and CMO
07 Aug 2022 //
PRNEWSWIRE
Transcenta to Present Interim Safety and Efficacy Data of the TST001
27 Jul 2022 //
PRNEWSWIRE
Transcenta was Selected to Present Preclinical Data of TST004 at the 2022 ISN
27 Jun 2022 //
PRNEWSWIRE
Transcenta Releases PI Data of TST001 in Combination with CAPOX
02 Jun 2022 //
ASIAONE
Nature Cancer Publishes Study Results by Transcenta and Jiao Tong University
30 May 2022 //
PRNEWSWIRE
Transcenta Begins Dosing in China Study of TST002 for Osteoporosis
28 Apr 2022 //
PRNEWSWIRE
Transcenta to Present Clinical Trial Data of TST001 and MSB0254 at 2022 ASCO
28 Apr 2022 //
PRNEWSWIRE
Transcenta Successfully Passed the Audit of EU Qualified for the MFG of TST001
21 Apr 2022 //
PRNEWSWIRE
Transcenta to Present Preclinical Data of TST005 at the 2022 AACR
30 Mar 2022 //
PRNEWSWIRE
Transcenta Enters Clinical Collaboration with BMS to Evaluate TST001+Opdivo
21 Mar 2022 //
PRNEWSWIRE
Transcenta Presented Safety/Tolerability, Prelim Anti-tumor Data of TST001
09 Mar 2022 //
PRNEWSWIRE
Transcenta Received IND Clearance from NMPA of its Anti-sclerostin TST002
25 Sep 2021 //
ASIAONE
Transcenta Held a Meeting and Initiated Phase IIa Clinical Trial of Claudin18.2
17 Aug 2021 //
PRNEWSWIRE
Transcenta Orphan Drug Designation Granted to TST001
28 Jul 2021 //
PRNEWSWIRE
Transcenta begins patient dosing in phase I trial of TST005
16 Jul 2021 //
PHARMABIZ
Transcenta Announces First Patient Dosed in Global Phase I Trial of TST005
14 Jul 2021 //
PRNEWSWIRE
Transcenta Announces First Patient Dosed in Global Phase I Trial of TST005
14 Jul 2021 //
PRNEWSWIRE
China NMPA accepts Transcenta’s IND application for TST002
08 Jul 2021 //
PHARMABIZ
Transcenta Announces NMPA Acceptance of IND Application of TST002
07 Jul 2021 //
PR NEWSWIRE
Transcenta Announces NMPA Acceptance of IND Application of TST002
07 Jul 2021 //
PR NEWSWIRE
Transcenta Announced Results of Phase I Clinical Study of PD-L1 Antibody MSB2311
20 May 2021 //
PRNEWSWIRE
Transcenta Announced the Results of the Phase I Study of PD-L1 Antibody MSB2311
18 May 2021 //
BIOSPACE
Transcenta Announces Updated Clinical Data from Phase I Study
14 May 2021 //
PRNEWSWIRE
Transcenta Received IND Clearance US FDA for Initiating Ph I Clinical Trial
21 Apr 2021 //
PRNASIA
US FDA clears Transcenta’s IND to initiate ph I trial for bi-functional
21 Apr 2021 //
PHARMABIZ
Transcenta Received IND Clearance from US FDA for Initiating Phase I Trial
20 Apr 2021 //
PRNASIA
Transcenta Received IND Clearance from US FDA for Initiating Phase I Trial
20 Apr 2021 //
PRNEWSWIRE
Transcenta Received IND Clearance from US FDA for Initiating PhI Clinical Trial
20 Apr 2021 //
PRNEWSWIRE
Transcenta Announced Successful First Patient Dosed in Phase I Study of TST001
19 Apr 2021 //
PRNEWSWIRE
